Marshall Wace, LLP Vaxxinity, Inc. Transaction History

Marshall Wace, LLP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$1.64 - $2.48 $725,209 - $1.1 Million	-442,201 Reduced 71.27%	178,258 $352,000
Q2 2022 Aug 15, 2022	BUY	$1.55 - $6.95 $961,711 - $4.31 Million	620,459 New	620,459 $973,000

198K

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.